Blood Glucose Monitoring Devices Market Global Report 2026

The blood glucose monitoring devices market size has grown rapidly in recent years. It will grow from $19.08 billion in 2025 to $21.02 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increasing prevalence of diabetes, growing aging population, rising awareness of diabetes management, expanding healthcare expenditure, and improving access to diagnostic devices.

The blood glucose monitoring devices market size is expected to see strong growth in the next few years. It will grow to $30.43 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to growing demand for continuous glucose monitoring, increasing adoption of home healthcare, rising focus on preventive healthcare, expanding reimbursement support for diabetes care, and increasing incidence of obesity and metabolic disorders. Major trends in the forecast period include growing adoption of continuous glucose monitoring systems, increasing preference for non-invasive glucose monitoring technologies, rising demand for personalized diabetes management, expanding home-based blood glucose monitoring, and greater focus on early detection and glycemic control.

The rising prevalence of diabetes worldwide is expected to drive the growth of the blood glucose monitoring devices market in the coming years. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels resulting from insufficient insulin production, impaired insulin action, or both. The rising prevalence of diabetes is attributed to increasing obesity rates, which significantly elevate the risk of developing type 2 diabetes. Blood glucose monitoring devices support diabetes management by enabling continuous glucose tracking, facilitating timely treatment adjustments, and reducing the risk of severe health complications. For instance, in March 2025, according to the UK Health Security Agency, a UK-based government public health organization, the GP-recorded prevalence of type 2 diabetes among adults aged 17 years and older in England increased from 6.8% in March 2023 to 7.0% in March 2024, representing an increase of approximately 2.9%. Therefore, the rising prevalence of diabetes worldwide is driving the growth of the blood glucose monitoring devices market.

Major companies operating in the blood glucose monitoring devices market are focusing on developing advanced products such as continuous glucose monitoring (CGM) systems to enable real-time glucose tracking, improve diabetes management, enhance patient convenience, and support better clinical outcomes. Continuous glucose monitoring (CGM) systems are wearable medical devices that continuously measure glucose levels in interstitial fluid and provide real-time glucose data, trends, and alerts to help individuals manage diabetes more effectively. For instance, in February 2023, Dexcom, a US-based medical device company, launched the Dexcom G7, a continuous glucose monitoring system. The device features a 30-minute sensor warm-up period, an all-in-one wearable sensor and transmitter design, and enhanced accuracy with a Mean Absolute Relative Difference (MARD) of approximately 8.2%. The system also enables real-time glucose sharing with caregivers and integration with compatible digital health platforms, improving the efficiency of diabetes management.

In August 2024, Abbott, a US-based manufacturer of continuous glucose monitors, partnered with Medtronic plc to integrate Abbott’s continuous glucose monitoring technology with Medtronic’s insulin delivery systems, enabling more connected and personalized diabetes management. The partnership aims to enhance blood glucose monitoring and insulin therapy by expanding interoperability between continuous glucose monitoring devices and automated insulin delivery systems for people with diabetes. Medtronic plc is an Ireland-based medical device company.

Major companies operating in the blood glucose monitoring devices market are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Medtronic plc, DexCom Inc., LifeScan Inc., Ascensia Diabetes Care Holdings AG, Sinocare Inc., Arkray Inc., Nova Biomedical Corporation, TaiDoc Technology Corporation, i-SENS Inc., ACON Laboratories Inc., Bionime Corporation, Apex Biotechnology Corporation, OSANG Healthcare Co. Ltd., OK Biotech Co. Ltd., ALL MEDICUS Co. Ltd., Senseonics Holdings Inc., Biolinq Incorporated, GlucoTrack Inc., Know Labs Inc., Afon Technology Ltd.

North America was the dominant region in the blood glucose monitoring devices market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the blood glucose monitoring devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the blood glucose monitoring devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.